查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1423795

皮癣菌甲癣治疗的全球市场 - 全球行业分析、规模、份额、增长、趋势、预测 (2031) - 按治疗类型、按适应症、按性别、按年龄组、按最终用户、按地区

Dermatophytic Onychomycosis Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:
出版日期: | 出版商: Fairfield Market Research | 英文 336 Pages | 商品交期: 2-5个工作天内

价格
简介目录

预计2024年至2031年全球皮癣菌甲癣治疗市场规模将大幅成长，预计2031年底将达到103亿美元。

2021年，用于治疗甲癣的药物占据了总市场份额的近四分之三，价值43.6亿美元。 这种优势凸显了严重依赖药物干预来解决这种常见的指甲疾病。

甲癣影响着全球约 10% 的人口，其中 60 岁以上老年人的盛行率尤其高。 影响因素包括週边免疫疾病、血管疾病和糖尿病，而糖尿病患者的风险明显较高。 此外，盛行率因地区而异，热带亚洲国家为 4% 至 5%，欧洲国家高达 17%。

对于皮癣菌甲癣治疗药物製造商来说，诊断和抗真菌测试不断增长的需求将在预测期内提供重大商机。 医疗保健专业人员和患者对指甲真菌感染的认识不断提高，加上正在进行的临床研究和药物管道开发，预计将进一步推动市场成长。

本报告调查了全球皮癣菌甲癣治疗市场，并提供了市场概述以及按治疗类型、适应症、性别、年龄组、最终用户、地区划分的趋势，并提供了有关公司竞争趋势的资讯进入市场。

目录

第 1 章执行摘要

第2章市场概述

  • 市场定义与细分
  • 市场动态
  • 价值链分析
  • 波特五力分析
  • 新冠肺炎 (COVID-19) 影响分析
  • 乌克兰和俄罗斯之间衝突的影响
  • 经济概况
  • 杵分析

第3章2018-2031年全球皮癣菌甲癣治疗市场前景

  • 2018-2031 年全球皮癣菌甲癣治疗市场前景（按治疗方法分类）、价值（十亿美元）
  • 2018-2031 年全球皮癣菌甲癣治疗市场展望（按适应症、价值（十亿美元））
  • 2018-2031 年全球皮癣菌甲癣治疗市场展望、性别、价值（十亿美元）
  • 2018-2031 年全球皮癣菌甲癣治疗市场展望（按年龄层、价值（十亿美元））
  • 2018-2031 年全球皮癣菌甲癣治疗市场展望，按分销管道划分，价值（十亿美元）
  • 2018-2031 年全球皮癣菌甲癣治疗市场前景（按地区、价值（十亿美元））

第4章北美皮癣菌甲癣治疗市场展望，2018-2031

第5章欧洲皮癣菌甲癣治疗市场展望，2018-2031

第 6 章亚太地区皮癣菌甲真菌病治疗市场展望，2018-2031

第 7 章拉丁美洲皮癣菌甲霉菌病治疗市场展望，2018-2031 年

第8章中东与非洲皮癣菌甲癣治疗市场前景，2018-2031

第9章竞争态势

  • 产品和指示热图
  • 2022 年公司市占率分析
  • 竞争对手仪表板
  • 公司简介
    • Bausch Health
    • Galderma S.A.
    • Novartis AG
    • Pfizer, Inc.
    • Moberg Pharma AB
    • Bayer AG
    • Dr. Reddy's Laboratories Ltd.
    • Cipla Ltd.
    • Medimetriks Pharmaceuticals, Inc.
    • Sanofi S.A.
    • GlaxoSmithKline Plc.
    • Teva Pharmaceutical industries Ltd.

第10章 附录

简介目录

The global dermatophytic onychomycosis therapeutics market is poised for substantial growth from 2024 to 2031. According to the latest industry analysis by Fairfield Market Research, is anticipated to reach an impressive valuation of US$ 10.30 billion by the end of 2031.

Market Dominance of Drug Therapies

In 2021, drugs used for treating dermatophytic onychomycosis accounted for nearly three-fourths of the overall market share, valued at US$ 4.36 billion. This dominance underscores the significant reliance on pharmaceutical interventions to address this common nail disorder.

Global Prevalence and Contributing Factors

Dermatophytic onychomycosis affects approximately 10% of the global population, with higher prevalence rates among older adults, particularly those above 60 years of age. Contributing factors include peripheral immunologic disorders, vascular disease, and diabetes mellitus, with diabetic patients facing a significantly higher risk. Moreover, prevalence rates vary across regions, ranging from 4%-5% in tropical Asian countries to up to 17% in European countries.

Future Opportunities and Market Dynamics

The forecast period presents lucrative opportunities for dermatophytic onychomycosis therapeutic drug manufacturers, driven by rising demand for diagnosis and antifungal testing. Increased awareness of fungal nail infections among healthcare professionals and patients, coupled with ongoing clinical studies and developments in drug pipelines, are expected to further propel market growth.

Challenges and Constraints

Despite the promising outlook, challenges such as low elasticity of demand and the non-life-threatening nature of the condition restrain market growth to some extent. Treatment failures, recurrent infections, and competition from alternative therapies pose additional challenges for stakeholders in the dermatophytic onychomycosis therapeutics market.

Regional Insights

In the United States, frequent FDA approvals and the high prevalence of chronic diseases such as diabetes contribute to the country's leading market share. Germany benefits from the presence of major industry players, while China's market growth is fueled by collaborative research efforts and strategic expansions in medical infrastructure.

Key Market Drivers and Competitive Landscape

The drugs segment remains the primary driver of market growth, with distal subungual onychomycosis emerging as the most prevalent indication. Key manufacturers are focused on expanding their product portfolios, obtaining regulatory approvals, and forging strategic partnerships to enhance market presence and revenue streams.

Key Segments Covered in Dermatophytic Onychomycosis Therapeutics Industry Survey:

Dermatophytic Onychomycosis Therapeutics Market by Treatment Type:

  • Dermatophytic Onychomycosis Therapeutic Drugs
    • Oral
  • Rx
  • OTC
    • Topical
  • Rx
  • OTC
  • Dermatophytic Onychomycosis Therapeutic Lasers
    • C02 Ablative Lasers
    • Nd:YAG Lasers
    • Dual-wave length near-infrared Lasers
  • Photodynamic Therapy

Dermatophytic Onychomycosis Therapeutics Market by Indication:

  • Distal Subungual Onychomycosis
  • White Superficial Onychomycosis
  • Proximal Subungual Onychomycosis
  • Candidal Onychomycosis
  • Total Dystrophic Onychomycosis

Dermatophytic Onychomycosis Therapeutics Market by Gender:

  • Male
  • Female

Dermatophytic Onychomycosis Therapeutics Market by Age Group:

  • 0-18 Years
  • 18-39 Years
  • 40-64 Years
  • 65 Years and Above

Dermatophytic Onychomycosis Therapeutics Market by End User:

  • Institutional Sales
    • Hospitals
    • Dermatology Clinics
  • Retail Sales
    • Retail Pharmacies
    • Drug Stores
    • Mail Order Pharmacies & Online Sales

Dermatophytic Onychomycosis Therapeutics Market by Region:

  • North America Dermatophytic Onychomycosis Therapeutics Market
  • Latin America Dermatophytic Onychomycosis Therapeutics Market
  • Europe Dermatophytic Onychomycosis Therapeutics Market
  • South Asia Dermatophytic Onychomycosis Therapeutics Market
  • East Asia Dermatophytic Onychomycosis Therapeutics Market
  • Oceania Dermatophytic Onychomycosis Therapeutics Market
  • Middle East & Africa Dermatophytic Onychomycosis Therapeutics Market

Table of Contents

1. Executive Summary

  • 1.1. Global Dermatophytic Onychomycosis Therapeutics Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Dermatophytic Onychomycosis Therapeutics Market Outlook, 2018 - 2031

  • 3.1. Global Dermatophytic Onychomycosis Therapeutics Market Outlook, by Treatment, Value (US$ Bn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Dermatophytic Onychomycosis Therapeutic Drugs
        • 3.1.1.1.1. Oral
          • 3.1.1.1.1.1. Rx
          • 3.1.1.1.1.2. OTC
        • 3.1.1.1.2. Topical
          • 3.1.1.1.2.1. Rx
          • 3.1.1.1.2.2. OTC
      • 3.1.1.2. Dermatophytic Onychomycosis Therapeutic Lasers
        • 3.1.1.2.1. C02 Ablative Lasers
        • 3.1.1.2.2. Nd:YAG Lasers
        • 3.1.1.2.3. Dual-wavelength near-infrared Lasers
      • 3.1.1.3. Photodynamic Therapy
  • 3.2. Global Dermatophytic Onychomycosis Therapeutics Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Distal Subungual Onychomycosis
      • 3.2.1.2. White Superficial Onychomycosis
      • 3.2.1.3. Proximal Subungual Onychomycosis
      • 3.2.1.4. Candidal Onychomycosis
      • 3.2.1.5. Total Dystrophic Onychomycosis
  • 3.3. Global Dermatophytic Onychomycosis Therapeutics Market Outlook, by Gender, Value (US$ Bn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. Male
      • 3.3.1.2. Female
  • 3.4. Global Dermatophytic Onychomycosis Therapeutics Market Outlook, by Age Group, Value (US$ Bn), 2018 - 2031
    • 3.4.1. Key Highlights
      • 3.4.1.1. 0-18 Years
      • 3.4.1.2. 18-39 Years
      • 3.4.1.3. 40-64 Years
      • 3.4.1.4. 65 Years and Above
  • 3.5. Global Dermatophytic Onychomycosis Therapeutics Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 3.5.1. Key Highlights
      • 3.5.1.1. Institutional Sales
        • 3.5.1.1.1. Hospitals
        • 3.5.1.1.2. Dermatology Clinics
      • 3.5.1.2. Retail Sales
        • 3.5.1.2.1. Retail Pharmacies
        • 3.5.1.2.2. Drug Stores
        • 3.5.1.2.3. Mail Order Pharmacies & Online Sales
  • 3.6. Global Dermatophytic Onychomycosis Therapeutics Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
    • 3.6.1. Key Highlights
      • 3.6.1.1. North America
      • 3.6.1.2. Europe
      • 3.6.1.3. Asia Pacific
      • 3.6.1.4. Latin America
      • 3.6.1.5. Middle East & Africa

4. North America Dermatophytic Onychomycosis Therapeutics Market Outlook, 2018 - 2031

  • 4.1. North America Dermatophytic Onychomycosis Therapeutics Market Outlook, by Treatment, Value (US$ Bn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Dermatophytic Onychomycosis Therapeutic Drugs
        • 4.1.1.1.1. Oral
          • 4.1.1.1.1.1. Rx
          • 4.1.1.1.1.2. OTC
        • 4.1.1.1.2. Topical
          • 4.1.1.1.2.1. Rx
          • 4.1.1.1.2.2. OTC
      • 4.1.1.2. Dermatophytic Onychomycosis Therapeutic Lasers
        • 4.1.1.2.1. C02 Ablative Lasers
        • 4.1.1.2.2. Nd:YAG Lasers
      • 4.1.1.3. Dual-wavelength near-infrared Lasers
  • 4.2. North America Dermatophytic Onychomycosis Therapeutics Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Distal Subungual Onychomycosis
      • 4.2.1.2. White Superficial Onychomycosis
      • 4.2.1.3. Proximal Subungual Onychomycosis
      • 4.2.1.4. Candidal Onychomycosis
      • 4.2.1.5. Total Dystrophic Onychomycosis
  • 4.3. North America Dermatophytic Onychomycosis Therapeutics Market Outlook, by Gender, Value (US$ Bn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. Male
      • 4.3.1.2. Female
  • 4.4. North America Dermatophytic Onychomycosis Therapeutics Market Outlook, by Age Group, Value (US$ Bn), 2018 - 2031
    • 4.4.1. Key Highlights
      • 4.4.1.1. 0-18 Years
      • 4.4.1.2. 18-39 Years
      • 4.4.1.3. 40-64 Years
      • 4.4.1.4. 65 Years and Above
  • 4.5. North America Dermatophytic Onychomycosis Therapeutics Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.5.1. Key Highlights
      • 4.5.1.1. Institutional Sales
        • 4.5.1.1.1. Hospitals
        • 4.5.1.1.2. Dermatology Clinics
      • 4.5.1.2. Retail Sales
        • 4.5.1.2.1. Retail Pharmacies
        • 4.5.1.2.2. Drug Stores
        • 4.5.1.2.3. Mail Order Pharmacies & Online Sales
    • 4.5.2. BPS Analysis/Market Attractiveness Analysis
  • 4.6. North America Dermatophytic Onychomycosis Therapeutics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 4.6.1. Key Highlights
      • 4.6.1.1. U.S. Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 4.6.1.2. U.S. Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
      • 4.6.1.3. U.S. Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
      • 4.6.1.4. U.S. Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
      • 4.6.1.5. U.S. Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 4.6.1.6. Canada Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 4.6.1.7. Canada Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
      • 4.6.1.8. Canada Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
      • 4.6.1.9. Canada Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
      • 4.6.1.10. Canada Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.6.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Dermatophytic Onychomycosis Therapeutics Market Outlook, 2018 - 2031

  • 5.1. Europe Dermatophytic Onychomycosis Therapeutics Market Outlook, by Treatment, Value (US$ Bn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Dermatophytic Onychomycosis Therapeutic Drugs
        • 5.1.1.1.1. Oral
          • 5.1.1.1.1.1. Rx
          • 5.1.1.1.1.2. OTC
        • 5.1.1.1.2. Topical
          • 5.1.1.1.2.1. Rx
          • 5.1.1.1.2.2. OTC
      • 5.1.1.2. Dermatophytic Onychomycosis Therapeutic Lasers
        • 5.1.1.2.1. C02 Ablative Lasers
        • 5.1.1.2.2. Nd:YAG Lasers
      • 5.1.1.3. Dual-wavelength near-infrared Lasers
  • 5.2. Europe Dermatophytic Onychomycosis Therapeutics Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Distal Subungual Onychomycosis
      • 5.2.1.2. White Superficial Onychomycosis
      • 5.2.1.3. Proximal Subungual Onychomycosis
      • 5.2.1.4. Candidal Onychomycosis
      • 5.2.1.5. Total Dystrophic Onychomycosis
  • 5.3. Europe Dermatophytic Onychomycosis Therapeutics Market Outlook, by Gender, Value (US$ Bn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Male
      • 5.3.1.2. Female
  • 5.4. Europe Dermatophytic Onychomycosis Therapeutics Market Outlook, by Age Group, Value (US$ Bn), 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. 0-18 Years
      • 5.4.1.2. 18-39 Years
      • 5.4.1.3. 40-64 Years
      • 5.4.1.4. 65 Years and Above
  • 5.5. Europe Dermatophytic Onychomycosis Therapeutics Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.5.1. Key Highlights
      • 5.5.1.1. Institutional Sales
        • 5.5.1.1.1. Hospitals
        • 5.5.1.1.2. Dermatology Clinics
      • 5.5.1.2. Retail Sales
        • 5.5.1.2.1. Retail Pharmacies
        • 5.5.1.2.2. Drug Stores
        • 5.5.1.2.3. Mail Order Pharmacies & Online Sales
    • 5.5.2. BPS Analysis/Market Attractiveness Analysis
  • 5.6. Europe Dermatophytic Onychomycosis Therapeutics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 5.6.1. Key Highlights
      • 5.6.1.1. Germany Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 5.6.1.2. Germany Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.6.1.3. Germany Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
      • 5.6.1.4. Germany Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
      • 5.6.1.5. Germany Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.6.1.6. U.K. Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 5.6.1.7. U.K. Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.6.1.8. U.K. Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
      • 5.6.1.9. U.K. Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
      • 5.6.1.10. U.K. Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.6.1.11. France Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 5.6.1.12. France Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.6.1.13. France Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
      • 5.6.1.14. France Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
      • 5.6.1.15. France Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.6.1.16. Italy Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 5.6.1.17. Italy Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.6.1.18. Italy Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
      • 5.6.1.19. Italy Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
      • 5.6.1.20. Italy Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.6.1.21. Turkey Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 5.6.1.22. Turkey Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.6.1.23. Turkey Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
      • 5.6.1.24. Turkey Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
      • 5.6.1.25. Turkey Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.6.1.26. Russia Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 5.6.1.27. Russia Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.6.1.28. Russia Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
      • 5.6.1.29. Russia Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
      • 5.6.1.30. Russia Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.6.1.31. Rest of Europe Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 5.6.1.32. Rest of Europe Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.6.1.33. Rest of Europe Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
      • 5.6.1.34. Rest of Europe Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
      • 5.6.1.35. Rest of Europe Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.6.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Dermatophytic Onychomycosis Therapeutics Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Dermatophytic Onychomycosis Therapeutics Market Outlook, by Treatment, Value (US$ Bn), 2018 - 2031
      • 6.1.1.1. Key Dermatophytic Onychomycosis Therapeutic Drugs
        • 6.1.1.1.1. Oral
          • 6.1.1.1.1.1. Rx
          • 6.1.1.1.1.2. OTC
        • 6.1.1.1.2. Topical
          • 6.1.1.1.2.1. Rx
          • 6.1.1.1.2.2. OTC
      • 6.1.1.2. Dermatophytic Onychomycosis Therapeutic Lasers
        • 6.1.1.2.1. C02 Ablative Lasers
        • 6.1.1.2.2. Nd:YAG Lasers
    • 6.1.2. Dual-wavelength near-infrared Lasers
  • 6.2. Asia Pacific Dermatophytic Onychomycosis Therapeutics Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Distal Subungual Onychomycosis
      • 6.2.1.2. White Superficial Onychomycosis
      • 6.2.1.3. Proximal Subungual Onychomycosis
      • 6.2.1.4. Candidal Onychomycosis
      • 6.2.1.5. Total Dystrophic Onychomycosis
  • 6.3. Asia Pacific Dermatophytic Onychomycosis Therapeutics Market Outlook, by Gender, Value (US$ Bn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Male
      • 6.3.1.2. Female
  • 6.4. Asia Pacific Dermatophytic Onychomycosis Therapeutics Market Outlook, by Age Group, Value (US$ Bn), 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. 0-18 Years
      • 6.4.1.2. 18-39 Years
      • 6.4.1.3. 40-64 Years
      • 6.4.1.4. 65 Years and Above
  • 6.5. Asia Pacific Dermatophytic Onychomycosis Therapeutics Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.5.1. Key Highlights
      • 6.5.1.1. Institutional Sales
        • 6.5.1.1.1. Hospitals
        • 6.5.1.1.2. Dermatology Clinics
      • 6.5.1.2. Retail Sales
        • 6.5.1.2.1. Retail Pharmacies
        • 6.5.1.2.2. Drug Stores
        • 6.5.1.2.3. Mail Order Pharmacies & Online Sales
    • 6.5.2. BPS Analysis/Market Attractiveness Analysis
  • 6.6. Asia Pacific Dermatophytic Onychomycosis Therapeutics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 6.6.1. Key Highlights
      • 6.6.1.1. China Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 6.6.1.2. China Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.6.1.3. China Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
      • 6.6.1.4. China Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
      • 6.6.1.5. China Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.6.1.6. Japan Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 6.6.1.7. Japan Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.6.1.8. Japan Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
      • 6.6.1.9. Japan Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
      • 6.6.1.10. Japan Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.6.1.11. South Korea Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 6.6.1.12. South Korea Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.6.1.13. South Korea Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
      • 6.6.1.14. South Korea Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
      • 6.6.1.15. South Korea Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.6.1.16. India Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 6.6.1.17. India Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.6.1.18. India Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
      • 6.6.1.19. India Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
      • 6.6.1.20. India Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.6.1.21. Southeast Asia Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 6.6.1.22. Southeast Asia Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.6.1.23. Southeast Asia Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
      • 6.6.1.24. Southeast Asia Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
      • 6.6.1.25. Southeast Asia Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.6.1.26. Rest of Asia Pacific Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 6.6.1.27. Rest of Asia Pacific Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.6.1.28. Rest of Asia Pacific Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
      • 6.6.1.29. Rest of Asia Pacific Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
      • 6.6.1.30. Rest of Asia Pacific Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.6.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Dermatophytic Onychomycosis Therapeutics Market Outlook, 2018 - 2031

  • 7.1. Latin America Dermatophytic Onychomycosis Therapeutics Market Outlook, by Treatment, Value (US$ Bn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Dermatophytic Onychomycosis Therapeutic Drugs
        • 7.1.1.1.1. Oral
          • 7.1.1.1.1.1. Rx
          • 7.1.1.1.1.2. OTC
        • 7.1.1.1.2. Topical
          • 7.1.1.1.2.1. Rx
          • 7.1.1.1.2.2. OTC
      • 7.1.1.2. Dermatophytic Onychomycosis Therapeutic Lasers
        • 7.1.1.2.1. C02 Ablative Lasers
        • 7.1.1.2.2. Nd:YAG Lasers
      • 7.1.1.3. Dual-wavelength near-infrared Lasers
  • 7.2. Latin America Dermatophytic Onychomycosis Therapeutics Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
      • 7.2.1.1. Distal Subungual Onychomycosis
      • 7.2.1.2. White Superficial Onychomycosis
      • 7.2.1.3. Proximal Subungual Onychomycosis
      • 7.2.1.4. Candidal Onychomycosis
      • 7.2.1.5. Total Dystrophic Onychomycosis
  • 7.3. Latin America Dermatophytic Onychomycosis Therapeutics Market Outlook, by Gender, Value (US$ Bn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Male
      • 7.3.1.2. Female
  • 7.4. Latin America Dermatophytic Onychomycosis Therapeutics Market Outlook, by Age Group, Value (US$ Bn), 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. 0-18 Years
      • 7.4.1.2. 18-39 Years
      • 7.4.1.3. 40-64 Years
      • 7.4.1.4. 65 Years and Above
  • 7.5. Latin America Dermatophytic Onychomycosis Therapeutics Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.5.1. Key Highlights
      • 7.5.1.1. Institutional Sales
        • 7.5.1.1.1. Hospitals
        • 7.5.1.1.2. Dermatology Clinics
      • 7.5.1.2. Retail Sales
        • 7.5.1.2.1. Retail Pharmacies
        • 7.5.1.2.2. Drug Stores
        • 7.5.1.2.3. Mail Order Pharmacies & Online Sales
    • 7.5.2. BPS Analysis/Market Attractiveness Analysis
  • 7.6. Latin America Dermatophytic Onychomycosis Therapeutics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 7.6.1. Key Highlights
      • 7.6.1.1. Brazil Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 7.6.1.2. Brazil Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.6.1.3. Brazil Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
      • 7.6.1.4. Brazil Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
      • 7.6.1.5. Brazil Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.6.1.6. Mexico Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 7.6.1.7. Mexico Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.6.1.8. Mexico Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
      • 7.6.1.9. Mexico Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
      • 7.6.1.10. Mexico Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.6.1.11. Argentina Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 7.6.1.12. Argentina Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.6.1.13. Argentina Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
      • 7.6.1.14. Argentina Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
      • 7.6.1.15. Argentina Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.6.1.16. Rest of Latin America Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 7.6.1.17. Rest of Latin America Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.6.1.18. Rest of Latin America Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
      • 7.6.1.19. Rest of Latin America Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
      • 7.6.1.20. Rest of Latin America Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.6.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Dermatophytic Onychomycosis Therapeutics Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Dermatophytic Onychomycosis Therapeutics Market Outlook, by Treatment, Value (US$ Bn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Dermatophytic Onychomycosis Therapeutic Drugs
        • 8.1.1.1.1. Oral
          • 8.1.1.1.1.1. Rx
          • 8.1.1.1.1.2. OTC
        • 8.1.1.1.2. Topical
          • 8.1.1.1.2.1. Rx
          • 8.1.1.1.2.2. OTC
      • 8.1.1.2. Dermatophytic Onychomycosis Therapeutic Lasers
        • 8.1.1.2.1. C02 Ablative Lasers
        • 8.1.1.2.2. Nd:YAG Lasers
      • 8.1.1.3. Dual-wavelength near-infrared Lasers
  • 8.2. Middle East & Africa Dermatophytic Onychomycosis Therapeutics Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Distal Subungual Onychomycosis
      • 8.2.1.2. White Superficial Onychomycosis
      • 8.2.1.3. Proximal Subungual Onychomycosis
      • 8.2.1.4. Candidal Onychomycosis
      • 8.2.1.5. Total Dystrophic Onychomycosis
  • 8.3. Middle East & Africa Dermatophytic Onychomycosis Therapeutics Market Outlook, by Gender, Value (US$ Bn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Male
      • 8.3.1.2. Female
  • 8.4. Middle East & Africa Dermatophytic Onychomycosis Therapeutics Market Outlook, by Age Group, Value (US$ Bn), 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. 0-18 Years
      • 8.4.1.2. 18-39 Years
      • 8.4.1.3. 40-64 Years
      • 8.4.1.4. 65 Years and Above
  • 8.5. Middle East & Africa Dermatophytic Onychomycosis Therapeutics Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.5.1. Key Highlights
      • 8.5.1.1. Institutional Sales
        • 8.5.1.1.1. Hospitals
        • 8.5.1.1.2. Dermatology Clinics
      • 8.5.1.2. Retail Sales
        • 8.5.1.2.1. Retail Pharmacies
        • 8.5.1.2.2. Drug Stores
        • 8.5.1.2.3. Mail Order Pharmacies & Online Sales
    • 8.5.2. BPS Analysis/Market Attractiveness Analysis
  • 8.6. Middle East & Africa Dermatophytic Onychomycosis Therapeutics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 8.6.1. Key Highlights
      • 8.6.1.1. GCC Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 8.6.1.2. GCC Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.6.1.3. GCC Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
      • 8.6.1.4. GCC Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
      • 8.6.1.5. GCC Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.6.1.6. South Africa Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 8.6.1.7. South Africa Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.6.1.8. South Africa Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
      • 8.6.1.9. South Africa Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
      • 8.6.1.10. South Africa Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.6.1.11. Egypt Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 8.6.1.12. Egypt Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.6.1.13. Egypt Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
      • 8.6.1.14. Egypt Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
      • 8.6.1.15. Egypt Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.6.1.16. Nigeria Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 8.6.1.17. Nigeria Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.6.1.18. Nigeria Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
      • 8.6.1.19. Nigeria Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
      • 8.6.1.20. Nigeria Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.6.1.21. Rest of Middle East & Africa Dermatophytic Onychomycosis Therapeutics Market by Treatment, Value (US$ Bn), 2018 - 2031
      • 8.6.1.22. Rest of Middle East & Africa Dermatophytic Onychomycosis Therapeutics Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.6.1.23. Rest of Middle East & Africa Dermatophytic Onychomycosis Therapeutics Market by Gender, Value (US$ Bn), 2018 - 2031
      • 8.6.1.24. Rest of Middle East & Africa Dermatophytic Onychomycosis Therapeutics Market by Age Group, Value (US$ Bn), 2018 - 2031
      • 8.6.1.25. Rest of Middle East & Africa Dermatophytic Onychomycosis Therapeutics Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.6.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Product vs Indication Heatmap
  • 9.2. Company Market Share Analysis, 2022
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Bausch Health
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Development
    • 9.4.2. Galderma S.A.
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Product Portfolio
      • 9.4.2.3. Financial Overview
      • 9.4.2.4. Business Strategies and Development
    • 9.4.3. Novartis AG
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Product Portfolio
      • 9.4.3.3. Financial Overview
      • 9.4.3.4. Business Strategies and Development
    • 9.4.4. Pfizer, Inc.
      • 9.4.4.1. Company Overview
      • 9.4.4.2. Product Portfolio
      • 9.4.4.3. Financial Overview
      • 9.4.4.4. Business Strategies and Development
    • 9.4.5. Moberg Pharma AB
      • 9.4.5.1. Company Overview
      • 9.4.5.2. Product Portfolio
      • 9.4.5.3. Financial Overview
      • 9.4.5.4. Business Strategies and Development
    • 9.4.6. Bayer AG
      • 9.4.6.1. Company Overview
      • 9.4.6.2. Product Portfolio
      • 9.4.6.3. Financial Overview
      • 9.4.6.4. Business Strategies and Development
    • 9.4.7. Dr. Reddy's Laboratories Ltd.
      • 9.4.7.1. Company Overview
      • 9.4.7.2. Product Portfolio
      • 9.4.7.3. Financial Overview
      • 9.4.7.4. Business Strategies and Development
    • 9.4.8. Cipla Ltd.
      • 9.4.8.1. Company Overview
      • 9.4.8.2. Product Portfolio
      • 9.4.8.3. Financial Overview
      • 9.4.8.4. Business Strategies and Development
    • 9.4.9. Medimetriks Pharmaceuticals, Inc.
      • 9.4.9.1. Company Overview
      • 9.4.9.2. Product Portfolio
      • 9.4.9.3. Financial Overview
      • 9.4.9.4. Business Strategies and Development
    • 9.4.10. Sanofi S.A.
      • 9.4.10.1. Company Overview
      • 9.4.10.2. Product Portfolio
      • 9.4.10.3. Financial Overview
      • 9.4.10.4. Business Strategies and Development
    • 9.4.11. GlaxoSmithKline Plc.
      • 9.4.11.1. Company Overview
      • 9.4.11.2. Product Portfolio
      • 9.4.11.3. Financial Overview
      • 9.4.11.4. Business Strategies and Development
    • 9.4.12. Teva Pharmaceutical industries Ltd.
      • 9.4.12.1. Company Overview
      • 9.4.12.2. Product Portfolio
      • 9.4.12.3. Financial Overview
      • 9.4.12.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations